AxoGen, Inc (NASDAQ:AXGN) has received a consensus rating of “Buy” from the ten analysts that are presently covering the stock, Marketbeat reports. Eight investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $35.57.
Several research analysts have weighed in on the stock. William Blair assumed coverage on shares of AxoGen in a report on Monday, February 5th. They issued an “outperform” rating on the stock. Jefferies Group increased their price target on shares of AxoGen to $45.00 and gave the company a “buy” rating in a report on Monday, March 19th. JMP Securities increased their price target on shares of AxoGen from $27.00 to $34.00 and gave the company a “market outperform” rating in a report on Thursday, March 1st. ValuEngine raised shares of AxoGen from a “buy” rating to a “strong-buy” rating in a report on Wednesday, May 2nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 target price (up from $37.00) on shares of AxoGen in a report on Tuesday, May 1st.
AxoGen stock traded up $1.05 during trading hours on Monday, hitting $45.80. The company had a trading volume of 8,215 shares, compared to its average volume of 535,700. The stock has a market cap of $1.48 billion, a P/E ratio of -146.29 and a beta of -0.04. The company has a quick ratio of 2.81, a current ratio of 3.32 and a debt-to-equity ratio of 0.82. AxoGen has a one year low of $14.25 and a one year high of $46.00.
AxoGen (NASDAQ:AXGN) last released its quarterly earnings results on Monday, April 30th. The medical equipment provider reported ($0.11) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.11). The firm had revenue of $17.30 million for the quarter, compared to analysts’ expectations of $17.16 million. AxoGen had a negative net margin of 18.83% and a negative return on equity of 61.66%. AxoGen’s quarterly revenue was up 41.8% on a year-over-year basis. equities analysts anticipate that AxoGen will post -0.38 earnings per share for the current fiscal year.
In other news, SVP Shawn F. Mccarrey sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 16th. The shares were sold at an average price of $43.47, for a total transaction of $434,700.00. Following the transaction, the senior vice president now directly owns 33,057 shares of the company’s stock, valued at $1,436,987.79. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 7.86% of the stock is currently owned by company insiders.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Rhumbline Advisers boosted its position in shares of AxoGen by 5.5% during the 1st quarter. Rhumbline Advisers now owns 25,538 shares of the medical equipment provider’s stock worth $932,000 after acquiring an additional 1,335 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. boosted its position in shares of AxoGen by 41.6% during the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,575 shares of the medical equipment provider’s stock worth $167,000 after acquiring an additional 1,345 shares in the last quarter. Northern Trust Corp boosted its position in shares of AxoGen by 0.5% during the 1st quarter. Northern Trust Corp now owns 332,844 shares of the medical equipment provider’s stock worth $12,149,000 after acquiring an additional 1,649 shares in the last quarter. Barclays PLC boosted its position in shares of AxoGen by 74.4% during the 1st quarter. Barclays PLC now owns 7,660 shares of the medical equipment provider’s stock worth $280,000 after acquiring an additional 3,269 shares in the last quarter. Finally, Proficio Capital Partners LLC boosted its position in shares of AxoGen by 5.6% during the 4th quarter. Proficio Capital Partners LLC now owns 67,600 shares of the medical equipment provider’s stock worth $1,913,000 after acquiring an additional 3,600 shares in the last quarter. 71.02% of the stock is currently owned by institutional investors.
AxoGen Company Profile
AxoGen, Inc develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.